ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results
  • All
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Adolescents and young adults
  • Advocacy
  • Anal cancer
  • Antioxidants
  • AYA
  • Bladder cancer
  • Blood cancers
  • Brain cancer
  • Breast cancer
  • Cancer care delivery
  • Caregiving
  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • ComboMATCH
  • Communication
  • COVID-19
  • DCIS
  • DCIS breast cancer
  • De-escalation
  • Esophagus cancer
  • Financial hardship
  • Gallbladder cancer
  • Gastroesophageal cancer
  • Geriatric oncology
  • GI cancer
  • Green tea
  • HAI chemotherapy
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Health equity
  • Hepatic arterial infusion chemotherapy.
  • HER2+ breast cancer
  • Hormone therapy
  • Imaging
  • Immune system therapy
  • Immunotherapy
  • Implementation science
  • In memory
  • Kidney cancer
  • Language
  • Late Effects
  • Leiomyosarcoma
  • Leukemia
  • LGBTQ+
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Mantle cell lymphoma
  • Melanoma
  • Men's health
  • Mesothelioma
  • Minimal residual disease
  • MRI
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloma
  • National Clinical Trials Network
  • NCI-MATCH
  • Neuropathy
  • Non-Hodgkin lymphoma
  • Non-small cell lung cancer
  • Nose and sinus cancer
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient care
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penile cancer
  • Peripheral T-cell lymphoma
  • Personalized medicine
  • Personalized screening
  • Personalized treatment
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Radiation therapy
  • Rare cancer
  • Rare cancers
  • Real-world data
  • Real-world evidence
  • Registry studies
  • Renal cell carcinoma
  • Research results
  • Sarcoma
  • Screening
  • Sexual and gender minorities
  • Side effects
  • Skin cancer
  • Smoldering multiple myeloma
  • Social genomics
  • Soft tissue sarcoma
  • Solid tumors
  • Squamous cell carcinoma
  • Surveillance
  • Survivorship
  • Symptom management
  • Symptom science
  • Targeted therapy
  • Throat cancer
  • Thyroid cancer
  • Triple-negative breast cancer
  • Tumor test
  • Upper tract urothelial cancer
  • Urothelial cancer
  • All
  • Diane Dragaud
  • ECOG-ACRIN Staff
  • ECOG-ACRIN Staff
July 2, 2024
July 2, 2024
Categories
  • Editorials

Helping patients navigate their cancer diagnosis, treatment, clinical trial options, and more

Patient navigation services have been shown to improve the patient experience and treatment outcomes
Do you like it?
0 Read more
March 26, 2024
March 26, 2024
Categories
  • Editorials

Improving the publication to practice pipeline: Effective dissemination of research results

Advocates can play an important role in communicating the results of clinical research to their communities
Do you like it?
0 Read more
October 9, 2023
Two women hugging under rainbow flag
October 9, 2023
Categories
  • Editorials

Reducing cancer health disparities for sexual and gender minorities

ECOG-ACRIN is part of a growing effort to reveal inequity among sexual and gender minorities, who face unique challenges and disparities related to cancer screening, care, and clinical trial access
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • Editorials

7 ways advocates have enhanced ECOG-ACRIN’s cancer research program

ECOG-ACRIN’s cancer research advocates recently reflected on their committee’s key accomplishments
Do you like it?
0 Read more
Prev page
1234567
Next page

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc